

MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS

12-14 September 2017, Crowne Plaza Hotel, Porto, Portugal

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR MVADS 2017

The drive for the new generation of vaccine therapies has precipitated a concurrent need for new and improved adjuvantation/delivery systems for these new vaccines. This new international conference will focus on updating the community on new adjuvant/delivery systems/technologies associated with developing modern vaccines strategies and vaccine research. There is now an urgent need for the development of these potent and safe adjuvants and delivery systems and MVADS 2017 will offer researchers a fresh forum to discuss this important topic in detail.

MVADS 2017 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups.

ADVISORY SCIENTIFIC PANEL

Edmund J. Remarque (*BPRC, Rijswijk, The Netherlands*)
 Dennis Christensen (*Statens Serum Institut, Copenhagen, Denmark*)
 Erik Lindblad (*Brenntag Biosector, Copenhagen, Denmark*)
 Stein Lokstad (*Brenntag Biosector, Copenhagen, Denmark*)
 Rob Lambkin-Williams (*Retroscreen Virology Ltd, London, UK*)
 Heather Davis (*Seqirus, Maidenhead, Berkshire, UK*)
 Derek O'Hagan (*Novartis Vaccines, Cambridge, Massachusetts, USA*)
 Adriana Baz Morelli (*CSL Ltd, Melbourne, Australia*)
 Nathalie Garcon (*BIOASTER Technology Research Institute, Lyon, France*)
 Niranjana Sardesai (*Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA*)
 Virgil Schijns (*Wageningen University, The Netherlands*)

Gary Ott (*Dynavax Inc., San Diego, California, USA*)
 Burkhard Becher (*University of Zurich, Zurich, Switzerland*)
 Stephane Ascarateil (*SEPPIC, Paris, France*)
 Geert Vanden Bossche (*UNIVAC LLC, Belgium*)
 Steve Reed (*IDRI, Seattle, USA*)
 Martin Bachmann (*University of Zurich, Switzerland & University of Oxford, UK*)
 Anna-Karin Maltais (*Eurocine Vaccines AB, Solna, Sweden*)
 Nicolas Havelange (*EVI, Heidelberg, Germany*)
 Jeffrey A. Hubbell (*University of Chicago, Chicago, Illinois, USA*)
 Behazine Combadiere (*Cimi-Paris, Paris, France*)
 Ken Ishii (*University of Osaka, Osaka, Japan*)

CONFERENCE SCOPE

Scientific Sessions:

Mechanistic Interpretations · Delivery · Formulation & Design · Modern Vaccines & Adjuvants · Safety · Regulation · Future Developments

SANOFI PASTEUR

NatureGeneTherapy.com
Gene-based vaccine technology

NIH National Institute of Allergy and Infectious Diseases

BILL & MELINDA GATES foundation

Janssen
PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

CSL™

BRENTAG

NOVARTIS
VACCINES

inovio
PHARMACEUTICALS

SEPPIC

IDRI

aldevron

EVI

UNIVAC

NOVAVAX

Pfizer

BIOASTER
MICROBIOLOGY TECHNOLOGY INSTITUTE

BIA
separations

Mucosis
Vaccines that mimic nature

izon
science

EUROCINE EV VACCINES

VAXART

MYMETICS
Vaccines for Tomorrow

BPRC

CUREVAC
the RNA people®

DNAvaccine.com

Abstract Submissions

The MVADS 2017 Advisory Scientific Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during MVADS 2017. The one page abstract should contain sufficient information for the Advisory Scientific Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (MVADS 2017 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 24th February 2017**. Authors will be informed of the status of their contribution(s) in March 2017.

Closing date for submissions intended for poster presentation: **Friday 25th August 2017**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to MVADS 2017. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at MVADS 2017. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- ☐ I wish to be placed on the mailing list to receive further information on MVADS 2017
- ☐ I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- ☐ My organisation is interested in sponsoring MVADS 2017
- ☐ Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- ☐ **INFLUENZA VACCINES FOR THE WORLD** – 19-21 April 2017, Lausanne, Switzerland
- ☐ **SKIN VACCINATION SUMMIT 2017** – 22-24 May 2017, Leiden, The Netherlands
- ☐ **PLANT-BASED VACCINES ANTIBODIES & BIOLOGICS** – 5-7 June 2017, Albufeira, Portugal
- ☐ **VACCINES FOR ENTERIC DISEASES** – 9-11 October 2017, Albufeira, Portugal

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, MVADS 2017, MEETINGS MANAGEMENT

The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com

Website: www.meetingsmanagement.com/mvads_2017